Core Viewpoint - Company shares of 基石药业-B (02616) rose over 4%, currently at 10.43 HKD with a trading volume of 109 million HKD, following the announcement of its CS2015 dual-specificity antibody being selected for presentation at the 2025 ACAAI annual scientific meeting in Orlando [1] Group 1: Company Pipeline and Developments - CS2015, a dual-specificity antibody targeting OX40L and TSLP, is recognized for its potential as a first-in-class/best-in-class treatment for type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease [1] - The upcoming ACAAI conference will take place from November 6 to 10 in Orlando, where CS2015 will be showcased through an electronic poster presentation and live oral report [1] Group 2: Market Potential and Clinical Advancements - 国投证券 highlighted that the early pipeline of the company includes several promising ADC products such as CS5007, CS5008, CS5005, CS5006, and CS5009, along with autoimmune pipeline products like CS2013 and CS2015, indicating a strong potential for differentiated offerings [2] - The clinical advancement of these products is expected to be closely monitored due to their high potential in the market [2]
基石药业-B涨超4% CS2015将亮相ACAAI 2025